Research

Purpose

This study was created to assess the safety and efficacy of a synthetic analogue of psilocybin for treatment-resistant depression. (Study Summary) This is a phase 3 multisite, active placebo, randomized, double-blind study. Participants will be enrolled for up to 62 weeks and will receive 2-4 dosing of 3 possible sizes of COMP360. Dosing is accompanied by psychotherapy.

Purpose

To better understand the long-term effects of novel clinical interventions for mood disorders (ketamine, ECT, TMS, etc.), including durability of treatment efficacy and potential long-term adverse events. (Study Summary) We are establishing a registry of individuals who receive IV ketamine infusions, TMS, ECT, and/or novel clinical treatments, and/or participate in clinical treatment trials for mood disorders to track their treatment progression and psychiatric symptoms over the span of one year.

Purpose

The purpose of this study is to evaluate the efficacy, safety, and tolerability of an investigational medication, (SPRAVATO^TM)

Study Summary

A clinical trial for Esketamine Nasal Spray, SPRAVATO^TM, as a standalone therapy for adult participants with treatment-resistant depression (TRD). Esketamine nasal spray (SPRAVATO^TM) is currently approved in the United States for use with an oral antidepressant for the treatment of TRD in adults.

Purpose

Depression is a serious but common condition that affects how you think, feel, and carry out your daily activities. We are studying an investigational oral medication to see if it reduces symptoms of moderate-to-severe depression in adults.

Study Summary

The Shoreline Study is a Phase 3, open-label, 1-year study of the safety and need for re-treatment with SAGE-217 in adults with major depressive disorder (MDD), as assessed by the Hamilton Depression Rating Scale (HAM-D).

Purpose

The purpose of the Bio-K study is to find out if the medication known as ketamine, can help the symptoms of depression in people living with major depression, bipolar disorder I or II. More specifically, we want to find out if some people have a better response to ketamine treatments than others and if we can predict that response (biomarkers).

Study Summary

A multi-site clinical trial looking at biomarkers of response to treatment with Intravenous ketamine, for adult patients with treatment refractory major depression or bipolar depression.

Purpose

To understand subjective experiences of participants using IV ketamine for treatment-resistant depression that go beyond clinically administered scales.

Study Summary

A sub-study of the Bio-K study, where enrolled participants of the Bio-K Study were asked about their subjective experiences while using IV ketamine and the effects of the treatment in their life after study completion. Participants were asked questions via Zoom using an in-depth interview guide.

Purpose

The IDEA study offers people self-help tools to improve their symptoms of depression and promote wellbeing such as a smartphone app, a computer-based online program, or an educational website and try to understand whether the tools are helpful to them.

Study Summary

Sixty depressed patients will be asked to select one electronic Mental Health (e-MH) resource from three offered in this pilot study. A Depression Care Manager will also be paired with patients, in part to motivate continued use of the resources, since lack of persistent use of e-MH resources has been a barrier. This study will provide real-world data on the implementation and effectiveness of e-health resources in a traditional healthcare delivery model.